Biolex

Biolex is a biopharmaceutical company that specializes in the development and commercialization of hard-to-make therapeutic proteins. The company utilizes its patented LEX System to produce these proteins in a cost-effective and efficient manner.

History

Biolex was founded in 1997 with the aim of revolutionizing the production of therapeutic proteins. The company's unique approach involves the use of the aquatic plant Lemna, which is capable of producing complex proteins in a controlled environment. This method, known as the LEX System, has been patented by Biolex and is the cornerstone of their production process.

LEX System

The LEX System is a proprietary protein production platform developed by Biolex. It utilizes the aquatic plant Lemna to produce therapeutic proteins. The system offers several advantages over traditional protein production methods, including lower costs, faster production times, and the ability to produce proteins that are difficult to manufacture using other methods.

Products

Biolex's product portfolio includes a range of therapeutic proteins that are used in the treatment of various diseases. These include Locteron, a controlled-release interferon used in the treatment of hepatitis C, and BLX-155, a direct-acting thrombolytic used in the treatment of acute peripheral arterial occlusion.

Partnerships

Biolex has formed strategic partnerships with several other biopharmaceutical companies to further develop and commercialize its products. These include partnerships with OctoPlus N.V., a Dutch drug delivery and drug development company, and UCB Pharma, a global biopharmaceutical company.

See also

• Biopharmaceutical
• Therapeutic protein
• Hepatitis C
• Peripheral arterial disease

<img src="//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Searchtool.svg/40px-Searchtool.svg.png" alt="Stub icon" width="40" height="40" />

This biopharmaceutical related article is a stub. You can help WikiMD by expanding it.